A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2001
11/29/2001	WO2001049674A3 Glycosidase inhibitors and preparation thereof
11/29/2001	WO2001049305A3 Process for obtaining thylakoids from plants, pure thylakoids and use thereof
11/29/2001	WO2001044465A3 Therapeutically useful synthetic oligonucleotides
11/29/2001	WO2001042471A8 Polypeptides and polynucleotides encoding same
11/29/2001	WO2001040309A3 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
11/29/2001	WO2001038566A3 Screening method for candidate drugs
11/29/2001	WO2001038347A3 Peptides having antiangiogenic activity
11/29/2001	WO2001031007A3 Nucleic acid molecules derived from rat brain and programmed cell death models
11/29/2001	WO2001028583A3 Melanoma vaccine and methods of making and using same
11/29/2001	WO2001025433A3 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
11/29/2001	WO2001023590A3 22196, a novel human aminopeptidase
11/29/2001	WO2001000864A3 Nucleic acid binding of multi-zinc finger transcription factors
11/29/2001	WO2000073469A3 Protein kinases
11/29/2001	WO2000061597A9 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
11/29/2001	WO2000061162A9 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
11/29/2001	WO2000059882A9 Anticancer calcium channel blockers
11/29/2001	WO2000055159A3 Substituted aza-oxindole derivatives
11/29/2001	WO2000041548A3 Methods for glucagon suppression
11/29/2001	WO2000010548A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001	US20010047083 Produced by hybridoma cell line ATCC No. HB12003 and progeny thereof; used in detection or treatment of carcinoembryonic antigen associated tumors
11/29/2001	US20010047032 Polyhydroxyaromatic or polyhydroxyheteroaromatic compounds are useful for treating Alzheimer's disease, Parkinson's disease and Lewy body disease and others
11/29/2001	US20010047021 Tetrasubstituted benzimidazole carbamates
11/29/2001	US20010047019 3-Aminopyrazole inhibitors of cyclin dependent kinases
11/29/2001	US20010047015 1H-1,2,4-Triazole derivative containing an aryl-substituted saturated 1,3-dioxane or 1,3-dioxepane ring
11/29/2001	US20010046993 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
11/29/2001	US20010046970 Inhibition of selectin binding
11/29/2001	US20010046961 Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel
11/29/2001	US20010046959 Method of treating cancer with anti-neurotrophin agents
11/29/2001	US20010046504 Film-coated tablet with cyclophosphamide as active compound, comprising in the core cyclophosphamide, one or more fillers, one or more dry binders but no preswollen starch, flow regulators and lubricants
11/29/2001	US20010046490 Cell surface molecule-induced macrophage activation
11/29/2001	US20010046481 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
11/29/2001	EP1143949A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001	DE10123349A1 New N-sulfonylated pipecolic acid derivatives, are matrix metalloprotease inhibitors useful e.g. for treating rheumatism, tumor progression, arteriosclerosis or inflammatory bowel disease
11/29/2001	DE10025045A1 Mittel zur Stimulation des Immunsystems Means for stimulation of the immune system
11/29/2001	DE10024451A1 Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung Pharmaceutical form of administration for peptides, process for their preparation and use
11/29/2001	DE10024384A1 Herstellung von dendritischen Zellen aus Rückenmarkstammzellen Preparation of dendritic cells from spinal cord stem cells
11/29/2001	DE10024383A1 Mit toxischen Substanzen beladene dendritische Zellen With toxic substances loaded dendritic cells
11/29/2001	CA2808215A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/29/2001	CA2429199A1 Drug metabolizing enzymes
11/29/2001	CA2413326A1 Use of baculovirus vectors in gene therapy
11/29/2001	CA2410593A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001	CA2410317A1 Methods for assaying gene imprinting and methylated cpg islands
11/29/2001	CA2410219A1 Prolonged release microspheres for injection delivery and preparation method
11/29/2001	CA2410096A1 Card domain containing polypeptides, encoding nucleic acids, and methods of use
11/29/2001	CA2410094A1 Compositions and methods for modulating tumor specific expression
11/29/2001	CA2409991A1 Bispecific immunoglobulin-like antigen binding proteins and method of production
11/29/2001	CA2409980A1 Conjugates of aminodrugs comprising an oxime bond
11/29/2001	CA2409868A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	CA2409688A1 Method for improving the cell protection
11/29/2001	CA2409430A1 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
11/29/2001	CA2409367A1 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
11/29/2001	CA2409299A1 Compositions and methods for the therapy and diagnosis of breast cancer
11/29/2001	CA2409298A1 Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
11/29/2001	CA2408883A1 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
11/29/2001	CA2408749A1 Drug screening systems and assays
11/29/2001	CA2408739A1 Novel proteins and nucleic acids encoding same, diagnostic and therapeutic uses
11/29/2001	CA2408709A1 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
11/29/2001	CA2408562A1 Dehydroascorbic acid formulations and uses thereof
11/29/2001	CA2408315A1 Aminoacyl trna synthetases
11/29/2001	CA2408141A1 Neurotransmitter transporters
11/29/2001	CA2408140A1 G-protein coupled receptors
11/29/2001	CA2408125A1 Synthetic peptides and uses therefore
11/29/2001	CA2407780A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
11/29/2001	CA2407570A1 Compositions and methods for delivery of a molecule into a cell
11/29/2001	CA2407028A1 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
11/29/2001	CA2405871A1 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
11/29/2001	CA2380935A1 Caspase inhibitors and uses thereof
11/28/2001	EP1158002A1 Human G-protein coupled receptor
11/28/2001	EP1157702A1 Compositions comprising DNA Damaging Agents and p53
11/28/2001	EP1157275A1 Novel transduction molecules and methods for using same
11/28/2001	EP1157126A1 Method for cloning signal transduction intermediates
11/28/2001	EP1157122A1 Anti-neoplastic compositions and uses thereof
11/28/2001	EP1157105A1 Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
11/28/2001	EP1157104A2 Pyk2 binding proteins
11/28/2001	EP1157076A1 Radioactive coating solutions, methods, and substrates
11/28/2001	EP1157043A1 Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions
11/28/2001	EP1157042A1 Production of tetravalent antibodies
11/28/2001	EP1157040A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
11/28/2001	EP1157036A1 Immunomodulating glycopeptide
11/28/2001	EP1157034A1 Process for production of diphtheria toxin
11/28/2001	EP1157031A1 Oligomers substituted by phosphonic acid ester, phosphonic acid or carbaborane functions and the corresponding pna monomers
11/28/2001	EP1157028A1 Novel substituted 11.beta steroid derivatives, method for preparing same and intermediates of said method, use as medicine and compositions containing them
11/28/2001	EP1157023A1 C-21 modified epothilones
11/28/2001	EP1157021A1 Sulfamato hydroxamic acid metalloprotease inhibitor
11/28/2001	EP1157019A1 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
11/28/2001	EP1157011A1 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
11/28/2001	EP1156999A1 Method for the preparation of a chiral-beta-amino ester
11/28/2001	EP1156855A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug
11/28/2001	EP1156835A2 Kit for radiolabeling proteins with yttrium-90
11/28/2001	EP1156828A1 Combination therapy for lymphoproliferative diseases
11/28/2001	EP1156827A2 Treatment of neoplastic diseases by radiation
11/28/2001	EP1156823A1 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
11/28/2001	EP1156818A2 Methods and compositions for regulating protein-protein interactions
11/28/2001	EP1156817A1 Controlling protein levels in eucaryotic organisms
11/28/2001	EP1156813A2 Reovirus for the treatment of cellular proliferative disorders
11/28/2001	EP1156797A2 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
11/28/2001	EP1156794A1 Methods and compositions for the treatment of neuropathic pain, tinnitus, and other disorders using r(-)-ketoprofen
11/28/2001	EP1156789A1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
11/28/2001	EP1156771A2 Interferon tau mutants and methods for making them
11/28/2001	EP0906268B1 Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors

1 ... 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 ... 2211